

Marked-Up Version Of Amended Claim

Additions to the text are indicated by underlining; deletions to the text are indicated by square brackets.

--198. (Twice Amended) A method of treating depression in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a MCH1 antagonist, wherein[:

- (a) (1) the MCH1 antagonist does not inhibit the activity of central monoamine oxidase A greater than 50 percent, at a concentration of 10mM; and (2) the MCH1 antagonist does not inhibit the activity of central monoamine oxidase B greater than 50 percent, at a concentration of 10mM; and
- (b)] the MCH1 antagonist binds to the MCH1 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to each of the following transporters: serotonin transporter, norepinephrine transporter, and dopamine transporter.--

--204. (Amended) The method of claim [198] 214, wherein the MCH1 antagonist does not inhibit the activity of central monoamine oxidase A greater than 60 percent.--

--205. (Amended) The method of claim [198] 214, wherein the MCH1 antagonist does not inhibit the activity of central monoamine oxidase B greater than 60 percent..

**EXHIBIT 1**

Beth Borowsky et al.  
Serial No. 09/899,732  
Filed: July 5, 2001  
page 1

--206. (Amended) The method of claim [198] 204, wherein the MCH1 antagonist does not inhibit the activity of central monoamine oxidase A greater than 50 [70] percent.--

--207. (Amended) The method of claim [198] 205, wherein the MCH1 antagonist does not inhibit the activity of central monoamine oxidase B greater than 50 [70] percent.--

**EXHIBIT 1**  
Beth Borowsky et al.  
Serial No. 09/899,732  
Filed: July 5, 2001  
page 2